| Theranexus–IRISA (FR): bioinformatics, 210904– collab using AI for targeting neuroglial interactions for drug discovery with Dyliss Group |
2019-04-09 |
| AgomAb Therapeutics–Advent France Biotechnology: investment, 201904 financing round Series A totalling €21m incl co-lead investor Advent France |
2019-04-03 |
| AgomAb Therapeutics–Boehringer: investment, 201904 financing round Series A totalling €21m incl co-investor BIVF |
2019-04-03 |
| AgomAb Therapeutics–Omnes Capital: investment, 201904 financing round Series A totalling €21m incl co-investor Omnes |
2019-04-03 |
| AgomAb Therapeutics–Pontifax: investment, 201904 financing round Series A totalling €21m incl co-investor Pontifax |
2019-04-03 |
| AgomAb Therapeutics–SEVERAL: investment, 201904 financing round Series A €21m co-led by V-Bio Ventures + Advent France Biotechnology |
2019-04-03 |
| AgomAb Therapeutics–V-Bio Ventures: investment, 201904 financing round Series A totalling €21m incl co-lead investor V-Bio Ventures |
2019-04-03 |
| Karuna–Sofinnova: investment, 201903–201904 financing round Series B totalling $80m incl $12m from new investor Sofinnova Investments |
2019-04-01 |
| Cellnovo–NONE: investment, 201903 in administration |
2019-03-28 |
| Polyneuron–New Enterprise Associates: investment, 201903 financing round Series A totalling CHF22.5m incl new + co-lead investor NEA |
2019-03-28 |
| Polyneuron–SEVERAL: investment, 201903 financing round Series A CHF22.5m led by Sofinnova Partners + incl NEA |
2019-03-28 |
| Polyneuron–Sofinnova: investment, 201903 financing round Series A totalling CHF22.5m incl new + lead investor Sofinnova Partners |
2019-03-28 |
| H4Orphan Pharma–Cerenis: investment, 201903–201904 excl merger negotations w Cerenis owning 59% of combined company TERMINATED 4/19 |
2019-03-27 |
| Pierre Fabre–Institut Curie: cancer immunotherapy, 201903– collab extension I-O drug target discovery with IRPF |
2019-03-21 |
| Pfizer–Vivet Therapeutics: VTX-801, collab developm €45m (incl acqu 15% share) + €560m milestones (incl acquisition of Vivet) |
2019-03-20 |
| Vivet Therapeutics–Pfizer: investment, 201903 acquisition 15% equity interest plus excl option to acquire all outstanding shares |
2019-03-20 |
| BPCE–SEVERAL: investment, 201903 first closing €na of Seventure Health for Life Capital II Fund with final target size of over €200m |
2019-03-05 |
| Novasep–Sartorius: chromatography, 201903– collab developm of systems for membrane chromatography SSB |
2019-03-05 |
| Anaeropharma Science–BPCE: investment, 201903 existent portfolio company of Seventure Partners |
2019-03-01 |
| Humedics–BPCE: investment, 201903 existent portfolio company of Seventure Partners |
2019-03-01 |
| MycoTechnology–BPCE: investment, 201903 existent portfolio company of Seventure Partners |
2019-03-01 |
| TargEDys–BPCE: investment, 201903 existent portfolio company of Seventure Partners |
2019-03-01 |
| Genfit–SEVERAL: investment, 201902–201903 private placement €9m with 500k ordinary shares at €18/share in Europe + outside North America |
2019-02-27 |
| Genfit–SEVERAL: investment, 201902–201903 US IPO $125m with 6.15m ADSs at $20.32/ADS at Nasdaq Global Select Market |
2019-02-27 |
| Ynsect–SEVERAL: investment, 201902 financing round Series C €110m ($1245m) led by Astanor Ventures |
2019-02-21 |
| BiomX–BPCE: investment, 201902 financing round Series B totalling $32m incl existing + co-lead investor Seventure Health for Life Capital fund |
2019-02-20 |
| BiomX–SEVERAL: investment, 201902 financing round Series B $32m led by existing investors OrbiMed + JJDC + Takeda Ventures et al |
2019-02-20 |
| BPCE–Yucatan: public relations, 201902 service existent media relations for Seventure Parnters in France by Agence Yucatan |
2019-02-20 |
| Arvelle Therapeutics–SEVERAL: investment, 201902 financing round Series A $180m with global investor syndicate |
2019-02-14 |
| Arvelle Therapeutics–SK Group: cenobamate, 201902– license excl for Europe $110m upfront + $430m milestones + royalties from SK Biopharmaceuticals |
2019-02-14 |
| CiToxLab–Charles River: investment, 201902– acquisition $448m in cash BINDING OFFER SIGNED |
2019-02-13 |
| Grey Wolf Therapeutics–Andera Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan |
2019-02-11 |
| Grey Wolf Therapeutics–Canaan Partners: investment, 201902 financing round Series A totalling £10m with Andera Partners + Canaan |
2019-02-11 |
| Grey Wolf Therapeutics–SEVERAL: investment, 201902 financing round Series A £10m with Andera Partners + Canaan |
2019-02-11 |
| Invisible Sentinel–Mérieux: investment, 201902 acquisition $75m in cash by bioMérieux |
2019-02-07 |
| Axial Biotherapeutics–BPCE: investment, 201902 financing round Series B totalling $25m incl new investor Seventure Partners |
2019-02-01 |
| Axial Biotherapeutics–SEVERAL: investment, 201902 financing round Series B $25m incl Seventure Partners |
2019-02-01 |
| Pharnext–CB Lux: investment, 201901 private placement €15m with 1.02m new shares at €14.7/share to CB Lux raising share from 21.12% to 27.79% |
2019-01-23 |
| ImaBiotech–Metabrain Research: preclinical research services, 201901– collab strategic partnership ADMET services in preclin metabolic disease models |
2019-01-17 |
| ImaBiotech–OCR (FR): preclinical research services, 201901– collab strategic partnership oncology research in pet tumors using bioanalytical imaging |
2019-01-17 |
| Nanobiotix–RooneyPartners: public relations, 201901 service existent US media relations by RooneyPartners |
2019-01-16 |
| Nanobiotix–SEVERAL: investment, 201901– filing of Form F-1 for registered public offering of shares + ADSs in US conditions to be determined later |
2019-01-16 |
| Sanofi–Biomunex: antibody technology, 201901– license €na to use BiXAb technology to generate + develop bi- + multi-specific antibodies |
2019-01-15 |
| Sophia Genetics–Alychlo: investment, 201901 financing round totalling $77m incl existing + co-investor Alychlo |
2019-01-04 |
| Sophia Genetics–Balderton Capital: investment, 201901 financing round totalling $77m incl existing + co-investor Balderton Capital |
2019-01-04 |
| Sophia Genetics–Generation Investment Management: investment, 201901 financing round totalling $77m incl new + lead investor Generation |
2019-01-04 |
| Sophia Genetics–Idinvest Partners: investment, 201901 financing round totalling $77m incl new + co-investor Idinvest Partners |
2019-01-04 |
| Sophia Genetics–SEVERAL: investment, 201901 financing round $77m incl new + lead investor Generation Investment Management LLP |
2019-01-04 |
| MycoTechnology–SEVERAL: investment, 201901 financing round Series C $30m |
2019-01-01 |
| Vedanta Biosciences–BMS: investment, 201812 financing round Series C totalling $27m incl new investor BMS |
2018-12-24 |
| Vedanta Biosciences–BPCE: investment, 201812 financing round Series C totalling $27m incl existing investor Seventure Partners |
2018-12-24 |
| Vedanta Biosciences–Gates Foundation: investment, 201812 financing round Series C totalling $27m incl new investor Gates Foundation |
2018-12-24 |
| Vedanta Biosciences–Invesco: investment, 201812 financing round Series C totalling $27m incl existing investor Invesco Asset Management |
2018-12-24 |
| Vedanta Biosciences–PureTech Health: investment, 201812 financing round Series C totalling $27m incl existing investor PureTech Health |
2018-12-24 |
| Vedanta Biosciences–Rock Springs Capital: investment, 201812 financing round Series C totalling $27m incl existing investor Rock Springs Capital |
2018-12-24 |
| Vedanta Biosciences–SEVERAL: investment, 201812 financing round Series C $27m Gates + BMS + Rock Springs Capital + Invesco + Seventure + PureTech |
2018-12-24 |
| France (govt)–Novartis: investment, 201812– proposed acquisition of CellforCure from LFB by Novartis |
2018-12-20 |
| Carmat–EU (govt): credit, 201812– EFSI €30m loan from EIB to move artificial heart towards marketing |
2018-12-17 |
| Kurma–France (govt): investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest |
2018-12-14 |
| Kurma–Idinvest Partners: investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest |
2018-12-14 |
| Kurma–NewCap: public relations, 201812 service existent by NewCap |
2018-12-14 |
| Kurma–Servier: investment, 201812 first closing of Kurma Biofund III incl cornerstone investors Servier + Bpifrance + Idinvest |
2018-12-14 |
| Kurma–SEVERAL: investment, 201812 first closing of Kurma Biofund III with target for final closing of €150m |
2018-12-14 |
| Pharvaris–Kurma: investment, 201812 existing founding investor Kurma Biofund II |
2018-12-14 |
| Step Pharma–Kurma: investment, 201812 existing founding investor Kurma Biofund II |
2018-12-14 |
| genOway–Merck (DE): CRISPR technology, 201812– collab strategic alliance €na incl ww excl license to produce + sell genome-edited rodent models |
2018-12-10 |
| Hookipa–Valneva: drug development services, 201812–202111 collab + manufacturing agreem for developm of immunotherapies with Valneva Sweden AB |
2018-12-06 |
| Sillages Paris–L’Oréal: investment, 201812 acquisition of minority share by BOLD fund as inaugural investment of BOLD |
2018-12-05 |
| Anagenesis–Alsace (govt): investment, 201812 financing round Series A 1st closing totalling €3m incl existing investor Cap Innov’Est |
2018-12-04 |
| Anagenesis–Boehringer: investment, 201812 financing round Series A 1st closing totalling €3m incl new investor BIVF |
2018-12-04 |
| Anagenesis–SEVERAL: investment, 201812 financing round Series A €3m 1st closing from BIVF + Cap Innov’Est |
2018-12-04 |
| Boehringer–Domain Therapeutics: drug discovery services, 201812– collab + license agreem €na discovery of GPCR-targeting CNS drugs |
2018-12-04 |
| Celyad–Bryan Garnier: investor conference, 201811 supply service Celyad participates at Bryan Garnier Annual Healthcare Conference in Paris |
2018-11-22 |
| Erytech–Infopro Digital: investor conference, 201811 supply service Erytech at Actionaria 2018 in Paris |
2018-11-22 |
| Stilla Technologies–Alize RP: public relations, 201811 service existent PR EU by Alize RP |
2018-11-20 |
| Stilla Technologies–BNP Paribas: investment, 201811 financing round Series A totalling €16m incl co-investor BNP Paribas Développement |
2018-11-20 |
| Stilla Technologies–Idinvest Partners: investment, 201811 financing round Series A totalling €16m incl co-investor Idinvest Partners |
2018-11-20 |
| Stilla Technologies–Illumina: investment, 201811 financing round Series A totalling €16m incl lead investor Illumina Ventures |
2018-11-20 |
| Stilla Technologies–Kurma: investment, 201811 financing round Series A totalling €16m incl co-investor Kurma Partners |
2018-11-20 |
| Stilla Technologies–LBO France: investment, 201811 financing round Series A totalling €16m incl co-investor LBO France |
2018-11-20 |
| Stilla Technologies–Paris Saclay Seeds: investment, 201811 financing round Series A totalling €16m incl co-investor Paris Saclay Seeds |
2018-11-20 |
| Stilla Technologies–SEVERAL: investment, 201811 financing round Series A €16m led by Illumina Ventures |
2018-11-20 |
| Erytech–Leucadia: investor conference, 201811 supply service Erytech at Jefferies London Healthcare Conference 2018 |
2018-11-14 |
| IntegraGen–Alphabet: bioinformatics, 201811 collab implementation of Sirius + Mercury genomic analsys tools in Google Cloud |
2018-11-12 |
| Q-Bioanalytic–Eurofins: investment, 201811 acquisition by Eurofins |
2018-11-01 |
| Sanofi–Denali Therapeutics: RIPK1 inhibitors, 201811– collab $125m upfront + >$1b + royalties RIPK1 inhibitors incl DNL 747 + DNL 758 |
2018-11-01 |
| Magnisense–SEVERAL: investment, 201810 financing round €5m from new + existing investors incl Meusinvest + Provestis + Concorde Capital + Minv |
2018-10-24 |
| Microbiotica–BPCE: investment, 201810 investment £4m by Seventure Partners’ Health for Life Capital Fund |
2018-10-24 |
| Enterome–Rx Communications: public relations, 201810 service existent IR by Rx Communications Group |
2018-10-23 |
| Acticor Biotech–CapDecisif: investment, 201810 financing round Series B totalling €15.3m incl existing + co-investor CapDecisif Management (HK) |
2018-10-17 |
| Acticor Biotech–China Medical System: investment, 201810 financing round Series B totalling €15.3m incl new + co-investor CMS Medical Venture |
2018-10-17 |
| Acticor Biotech–Mirae Asset: investment, 201810 financing round Series B totalling €15.3m incl new + co-investor Mirae Asset Capital Co Ltd |
2018-10-17 |
| Acticor Biotech–NewCap: public relations, 201810 service existent by NewCap |
2018-10-17 |
| Acticor Biotech–Newton Biocapital: investment, 201810 financing round Series B totalling €15.3m incl new + lead investor Newton Biocapital |
2018-10-17 |
| Acticor Biotech–PERSON: investment, 201810 financing round Series B totalling €15.3m incl new + co-investor A&B (HK) |
2018-10-17 |
| Acticor Biotech–SEVERAL: investment, 201810 financing round Series B €15.3m led by new investor Newton Biocapital |
2018-10-17 |
| Erytech–EZIL: investor conference, 201810 supply service Erytech at European Large & Midcap Event in Paris |
2018-10-09 |
| Rgenix–SEVERAL: investment, 201810 financing round Series C $40m led by Lepu Medical + incl Novo Holdings + Sofinnova Partners et al |
2018-10-09 |
| Sitryx Therapeutics–GSK: investment, 201810 financing round Series A totalling $30m incl co-investor GSK |
2018-10-08 |
| Sitryx Therapeutics–Longwood Fund: investment, 201810 financing round Series A totalling $30m incl co-investor Longwood Fund |
2018-10-08 |
![[LSF] Life-Sciences-France.com - The French Life Sciences Web Portal](/images/basics/lsf-life-sciences-france-portal-logo-2015.jpg){kind=logo}
Date![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px](/banner/iito-20181119-600-060-lsus-life-sciences-usa-com-beta.jpg)
![Picture [iito] LSUS iitoLifeScience Transatlantic Life Sciences 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
